DDX5-targeting fully human monoclonal autoantibody inhibits proliferation and promotes differentiation of acute promyelocytic leukemia cells by increasing ROS production

Acute promyelocytic leukemia (APL) therapy involves the compounds cytotoxic to both malignant tumor and normal cells. Relapsed APL is resistant to subsequent chemotherapy. Novel agents are in need to kill APL cells selectively with minimal toxicity. DDX5 has been recognized to be a novel target to s...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Jing, You, Yan-Qiu, Ma, Yan-Xiu, Kang, Yan-Hua, Wu, Tian, Wu, Xiang-Ji, Hu, Xiao-Xiao, Meng, Qiao-Hong, Huang, Yin, Zhang, Na, Pan, Xiao-Ben
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7371707/
https://www.ncbi.nlm.nih.gov/pubmed/32690860
http://dx.doi.org/10.1038/s41419-020-02759-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7371707/
https://www.ncbi.nlm.nih.gov/pubmed/32690860
http://dx.doi.org/10.1038/s41419-020-02759-5

Ejemplares similares